There is provided inter alia a compound selected from Compounds (1 to 203) and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a disease selected from the group consisting of a positive-sense single-stranded RNA vims ((+)ssRNA vims) infection, a disease associated with a positive-sense single-stranded RNA virus ((+)ssRNA vims) infection and lung inflammation.

There is provided inter alia a compound selected from Compounds (1 to 203) and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a disease selected from the group consisting of a positive-sense single-stranded RNA vims ((+)ssRNA vims) infection, a disease associated with a positive-sense single-stranded RNA virus ((+)ssRNA vims) infection and lung inflammation.

Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H.sub.1-receptor agonist, a histamine H.sub.2-receptor agonist, a histamine H.sub.3-receptor antagonist, or a β.sub.2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H.sub.1-receptor agonist, a histamine H.sub.2-receptor agonist, a histamine H.sub.3-receptor antagonist, or a β.sub.2-adrenoreceptor agonist.

Provided herein is a pharmaceutical composition comprising two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H.sub.1-receptor agonist, a histamine H.sub.2-receptor agonist, a histamine H.sub.3-receptor antagonist, or a β.sub.2-adrenoreceptor agonist. Also provided herein is a method of treating, preventing, or ameliorating a cardiovascular disease in a subject, comprising administering to the subject in need thereof two or more compounds, wherein each compound is independently a phosphodiesterase inhibitor, an adenosine receptor antagonist, a calcium channel blocker, a histamine H.sub.1-receptor agonist, a histamine H.sub.2-receptor agonist, a histamine H.sub.3-receptor antagonist, or a β.sub.2-adrenoreceptor agonist.

The present invention provides an inhalation-type pharmaceutical composition for gout and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising colchicine, allopurinol, probenecid, sulfinpyrazone, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

The present invention provides an inhalation-type pharmaceutical composition for gout and preparation method thereof, comprising a first gas and an atomized medicine. The first gas comprises hydrogen. The gas volume concentration of hydrogen in the inhalation-type pharmaceutical composition is between 2 to 96%. The atomized medicine is selected from a group comprising colchicine, allopurinol, probenecid, sulfinpyrazone, and any combination thereof. The inhalation-type pharmaceutical composition of the present invention can remove harmful radicals in the body of the patient through the use of hydrogen while also increases the absorption effect of the medicine for the patient by using an atomized medicine. At the same time, because the use of the small amount of the vaporized pharmaceutical liquid can indirectly reduce the side effects on the user.

Disclosed herein is a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling. The formulation comprises ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application for relief of neuropathy symptoms. Disclosed herein is a method of making a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base suitable for topical application. Disclosed herein is a method of using a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application to relieve symptoms of neuropathy.

Disclosed herein is a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling. The formulation comprises ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application for relief of neuropathy symptoms. Disclosed herein is a method of making a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base suitable for topical application. Disclosed herein is a method of using a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application to relieve symptoms of neuropathy.

Disclosed herein is a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling. The formulation comprises ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application for relief of neuropathy symptoms. Disclosed herein is a method of making a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base suitable for topical application. Disclosed herein is a method of using a formulation for relief of symptoms associated with neuropathy, such as pain, burning, itching, or tingling, the formulation comprising ketamine HCL, gabapentin, piroxicam, clonidine HCL, nifedipine, and lidocaine HCL in a cream base for topical application to relieve symptoms of neuropathy.

A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.